Neural-net Artificial Pancreas (NAP)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-30

Study Completion Date

2023-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is intended to assess a Neural-net Artificial Pancreas (NAP) implementation of an established AP controller - the University of Virginia Model Predictive Control Algorithm (UMPC). The health outcomes achieved on NAP will be compared to the health outcomes achieved on UMPC in a randomized crossover design. The investigators will consent up to 20 participants, ages ≥18.0, with a goal of completing 15 participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery

NCT01492062

Type 1 Diabetes Mellitus

WITHDRAWN NA

Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients

NCT03353792

Type1 Diabetes Mellitus

TERMINATED NA

Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes

NCT04545567

Type 1 Diabetes

COMPLETED NA

An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas

NCT02536950

Diabetes Mellitus, Type 1

COMPLETED NA

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

NCT04877730

Type 1 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will follow a randomized cross-over design assessing glycemic control on a Neural-net Artificial Pancreas (NAP), compared to the previously tested University of Virginia Model Predictive Control (UMPC) algorithm, in a supervised hotel setting:

The study will involve Tandem t:slim X2 Control-IQ (CIQ) users who will continue to use their CIQ systems, except during the hotel sessions, which will use the DiAs prototyping platform, connected to a Tandem t:AP research pump and a Dexcom G6 sensor, and implementing NAP or UMPC. The study sensor will be the same sensor used by CIQ - it will be disconnected from CIQ and connected to DiAs.

Following enrollment, one week of automated insulin delivery (AID) data will be downloaded from the participants' pumps or t:connect accounts and will be used to establish a baseline and initialize the control algorithms. Participants will be then studied at a local hotel for 20 hours, including an 18-hour experiment, randomly receiving either NAP or UMPC. Participants will then receive the opposite intervention either sequentially during the same hotel stay, or in a second hotel stay up to 28 days following the first hotel stay. During these 18-hour hotel sessions participants will be followed to compare blood glucose control on NAP vs. UMPC. The study meals and activities will be kept the same between study sessions.

The investigators will analyze non-inferiority of NAP compared to UMPC, but this pilot feasibility study is not powered to formally test noninferiority. The primary outcome is percent time in range (TIR) (70 to 180 mg/dL) on NAP vs UMPC. Secondary outcomes include frequency of hypoglycemia (time below range = TBR) and hyperglycemia (time above range = TAR), as well as other safety and control metrics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized crossover: Participants will be randomized to two groups differing by the order of controller use: Group A: NAP, followed by UMPC; Group B: UMPC, followed by NAP.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NAP first, then UMPC

Participants will use the Neural Net Artificial Pancreas (NAP) algorithm for 18 hours. Then switch to the University of Virginia Model-Predictive Control (UMPC) for 18 hours.

Group Type EXPERIMENTAL

Neural-net Artificial Pancreas

Intervention Type DEVICE

NAP is a neural-net implementation of the previously tested UMPC algorithm (below).

University of Virginia Model Predictive Control

Intervention Type DEVICE

A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.

UMPC first, then NAP

Participants will use the UMPC for 18 hours, then switch to NAP for 18 hours.

Group Type EXPERIMENTAL

Neural-net Artificial Pancreas

Intervention Type DEVICE

NAP is a neural-net implementation of the previously tested UMPC algorithm (below).

University of Virginia Model Predictive Control

Intervention Type DEVICE

A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neural-net Artificial Pancreas

NAP is a neural-net implementation of the previously tested UMPC algorithm (below).

Intervention Type DEVICE

University of Virginia Model Predictive Control

A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NAP UMPC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18.0 at time of consent.
2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year.
3. Currently using insulin for at least six months.
4. Currently using the Control-IQ automated insulin delivery system for at least one mont.
5. Hemoglobin A1c of ≤9%.
6. Using insulin parameters such as insulin to carb ratio and correction factor consistently in order to dose insulin for meals or corrections.
7. Access to internet and willingness to upload data during the study as needed.
8. If female of childbearing potential and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential within 24 hours prior to initiating the experimental algorithms. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
9. Willingness to use the University of Virginia Diabetes Assistant system throughout study session.
10. Willingness to use personal Lispro (Humalog) or aspart (Novolog) during the study session.
11. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial (including Sodium-glucose cotransporter-2 inhibitors, metformin/biguanides, glucagon-like peptide-1 receptor agonists, Pramlintide, Dipeptidyl peptidase-4 inhibitors, Sulfonylureas and nutraceuticals).
12. Willingness to reschedule the hotel portion of the study if placed on systemic steroids (e.g. intravenous injection, intramuscular injection, intra-articular or oral routes).
13. An understanding and willingness to follow the protocol and signed informed consent.

Exclusion Criteria

1. History of Diabetic Ketoacidosis (DKA) in the 12 months prior to enrollment.
2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment.
3. Currently pregnant or intent to become pregnant during the trial.
4. Currently breastfeeding.
5. Currently being treated for a seizure disorder.
6. Treatment with Meglitinides/Sulfonylureas at the time of hotel study.
7. Use of metformin/biguanides, glucagon-like peptide-1 agonists, Pramlintide, Dipeptidyl peptidase-4 inhibitors, Sodium-glucose cotransporter-2 inhibitors, or nutraceuticals intended for glycemic control with a change in dose in the past month.
8. History of significant cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted or previous ablation of arrhythmia without recurrence which may be permitted) or active cardiovascular disease.
9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:

1. Inpatient psychiatric treatment in the past 6 months.
2. Presence of a known adrenal disorder.
3. Uncontrolled thyroid disease.
10. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No